Paul Vukelic

ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA.

FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA.

Parata Systems LLC engages in the provision of pharmacy technology solutions. It offers pharmacy automation, medication management, pharmacy workflow integration, medication packaging, and long term care medication solutions. The company was founded by Jess Eberdt and W. L. Townsend in 2001 and is headquartered in Durham, NC.

Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

The Association of American Rhodes Scholars operates as a non-profit organization. The firm serves American Rhodes Scholars and facilitates building connections, sharing experiences and extending perspectives through events, publications, networks and the web. The company is headquartered in Vienna, VA.

HAP Investments LLC acquires and develops mid sized residential and commercial properties. The firm specializes in global real estate markets, property development, real estate finance and law. The company was founded by Eran Polack, Amir Hasid, and Nir Amsel in 2010 and is headquartered in New York, NY.

Clarion UX provides trade show management services. It offers strategic planning, exhibit sales, marketing including research and customer insights, operations, exhibitor and attendee promotions and services, media relations, conference management, and database development and management. The company was founded by Douglas A. Miller and Timothy C. von Gal in 1995 and is headquartered in Kennesaw, GA.

Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD.

Sydnexis, Inc. engages in the production of ophthalmic pharmaceutical products. The company was founded by Gregory Isaac Ostrow in 2014 and is headquartered in San Diego, CA.

Panther Pharmaceuticals, Inc. operates as a biotechnology company. The company is headquartered in Cambridge, MA.

Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA.

Bespoke, Inc. sells eyewear and provides assistance to retailers and eyewear brands to improve and expand their reach in the industry. The private company is based in San Francisco, CA. The company offers a virtual try-on feature and precise frame and lens measurements through their scan technology. The company aims to help both in-store and online businesses improve their customer experience and reduce return rates. The company was founded by Eric Varady, who has been the CEO since incorporation.

Part of Aviceda Therapeutics, Inc., Aviceda Ophthalmics, Inc. develops disease-modifying medicines through innovative technology platforms. The company is based in Cambridge, MA. The company was founded in 2019. The CEO is Mohamed A. Genead.